Propensity weighted regression analysis showed that MBC patients with TNBC (HR 1.22, CI 1.21–1.24; p < 0.0001) and HER2+ BC (HR 2, CI 1.98–2.03; p < 0.0001) had a higher risk of mortality compared with FBC; however, MBC patients with HR+/HER2-BC (HR 0.78, CI 0.78–0.79; p < 0.0001) had a lower risk of mortality compared with FBC after adjusting for confounding variables. Here, ERBB2 is linked to breast cancer.